Nano-drug sustained release preparation for treating malignant tumor and preparation method thereof

Abstract

The invention discloses a nano-drug sustained release preparation for treating a malignant tumor and a preparation method thereof. The preparation is formed by an epidermal growth factor receptor tyrosine kinase inhibitor with the tumor growth inhibition effect, a high-molecular polymer and a freeze-drying protective additive. The preparation method is simple, suitable for the large-scale production, and particularly suitable for preparing an antitumor drug nano-preparation with the characteristics of long blood circulation time, biodegradation in vivo, slow release of drugs, and passive targeting. The antitumor nano-drug sustained release preparation prepared by the method is suitable for the management by using modes, such as intravenous injection, intramuscular injection, intratumor injection and peritumoral injection, and applied to the treatment of the malignant solid tumors, such as lung cancer, liver cancer, gastric cancer, intestinal cancer, esophagus cancer, nasopharyngeal cancer, uterus cancer, breast cancer, glioma cancer, ovarian cancer, and prostate cancer, and has the good application prospect.

Description

technical field [0001] The invention relates to the field of medical technology, and relates to a sustained-release nano drug preparation for treating malignant tumors and a preparation method thereof Background technique [0002] In recent years, the incidence and mortality of malignant tumors in my country have remained high, and the situation has become more and more serious. In particular, the incidence and mortality of lung cancer have been rising year by year, ranking first among malignant tumors and seriously threatening human health. For the treatment of lung cancer, there are mainly surgical treatment, chemotherapy, radiotherapy, targeted therapy, etc. Among various treatment methods, targeted therapy is an important means for the treatment of lung adenocarcinoma. In recent years, based on the study of the molecular level of tumor lesions, many new therapeutic targets have been discovered, which provides the possibility for the development of new drugs with high eff...

AI Technical Summary

Problems solved by technology

But along with the widespread application of gefitinib and more and more studies show, gefitinib oral formulations have following defects: poor water solubility, solubility is greatly affected by pH; maximum bioavailability is only 59% ; slow oral absorption, T max About 3-7 hours; patients need long-term medication, poor tolerance; oral administration is widely distributed, and there are many adverse reactions, so it is difficult to make the drug exert a better therapeutic effect on the local tumor

Images